NCT04240639View on ClinicalTrials.gov

An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

NAUnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions
Neoplasms of the Prostate
Interventions
DEVICE

AuroShell particle infusion

Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.

Trial Locations (8)

10075

Lenox Hill/Northwell Health System, New York

27710

Duke University School of Medicine, Durham

41195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic Urology, Rochester

63110

Washington University in St. Louis, St Louis

77030

University of Texas Medical School at Houston, Houston

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

Sponsors
All Listed Sponsors
lead

Nanospectra Biosciences, Inc.

INDUSTRY

NCT04240639 - An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue | Biotech Hunter | Biotech Hunter